Q & A with Dr Michael Winlo about Emyria's unique over-the-counter strategy & dosing for EMD-RX5 Ph. 3 Clinical Trial

A major milestone for Emyria with dosing commencing for the Phase 3 Clinical Trial of Ultra-Pure CBD medication EMD-RX5 - a pivotal step towards our goal of TGA registration.  EMD-RX5 aims to treat mild anxiety & stress and be available over the counter.

Take a look at this latest Q&A video where Dr Michael Winlo answers some FAQs on Emyria's unique over-the-counter strategy and the competitive advantages it provides.  "By analysing our real-world data, we can be really targeted on what dose form and what dose strength we think will be most effective and most likely to pass the rigorous examination of a clinical study.," he says.

We are the only group targeting symptoms of psychological distress in patients with chronic pain."